175 related articles for article (PubMed ID: 32976482)
1. A greedy classifier optimization strategy to assess ion channel blocking activity and pro-arrhythmia in hiPSC-cardiomyocytes.
Raphel F; De Korte T; Lombardi D; Braam S; Gerbeau JF
PLoS Comput Biol; 2020 Sep; 16(9):e1008203. PubMed ID: 32976482
[TBL] [Abstract][Full Text] [Related]
2. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
3. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
4. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Qu Y; Vargas HM
Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
[TBL] [Abstract][Full Text] [Related]
5. Assessing proarrhythmic potential of environmental chemicals using a high throughput in vitro-in silico model with human induced pluripotent stem cell-derived cardiomyocytes.
Lin HC; Rusyn I; Chiu WA
ALTEX; 2024 Jan; 41(1):37-49. PubMed ID: 37921411
[TBL] [Abstract][Full Text] [Related]
6. Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay.
da Rocha AM; Creech J; Thonn E; Mironov S; Herron TJ
Toxicol Sci; 2020 Feb; 173(2):402-415. PubMed ID: 31764978
[TBL] [Abstract][Full Text] [Related]
7. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
Jæger KH; Wall S; Tveito A
PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
[TBL] [Abstract][Full Text] [Related]
8. A deep learning platform to assess drug proarrhythmia risk.
Serrano R; Feyen DAM; Bruyneel AAN; Hnatiuk AP; Vu MM; Amatya PL; Perea-Gil I; Prado M; Seeger T; Wu JC; Karakikes I; Mercola M
Cell Stem Cell; 2023 Jan; 30(1):86-95.e4. PubMed ID: 36563695
[TBL] [Abstract][Full Text] [Related]
9. Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes.
Zeng H; Roman MI; Lis E; Lagrutta A; Sannajust F
J Pharmacol Toxicol Methods; 2016; 81():217-22. PubMed ID: 27222351
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
Yamamoto W; Asakura K; Ando H; Taniguchi T; Ojima A; Uda T; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yoshinaga T; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
PLoS One; 2016; 11(12):e0167348. PubMed ID: 27923051
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
Bai S; Pei J; Chen K; Zhao Y; Cao H; Tian L; Ma Y; Dong H
SLAS Discov; 2021 Mar; 26(3):364-372. PubMed ID: 32914673
[TBL] [Abstract][Full Text] [Related]
12. Modelling Torsade de Pointes arrhythmias in vitro in 3D human iPS cell-engineered heart tissue.
Kawatou M; Masumoto H; Fukushima H; Morinaga G; Sakata R; Ashihara T; Yamashita JK
Nat Commun; 2017 Oct; 8(1):1078. PubMed ID: 29057872
[TBL] [Abstract][Full Text] [Related]
13. Safety pharmacology studies using EFP and impedance.
Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
[TBL] [Abstract][Full Text] [Related]
14. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
Blinova K; Dang Q; Millard D; Smith G; Pierson J; Guo L; Brock M; Lu HR; Kraushaar U; Zeng H; Shi H; Zhang X; Sawada K; Osada T; Kanda Y; Sekino Y; Pang L; Feaster TK; Kettenhofen R; Stockbridge N; Strauss DG; Gintant G
Cell Rep; 2018 Sep; 24(13):3582-3592. PubMed ID: 30257217
[TBL] [Abstract][Full Text] [Related]
15. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.
Ando H; Yoshinaga T; Yamamoto W; Asakura K; Uda T; Taniguchi T; Ojima A; Shinkyo R; Kikuchi K; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
J Pharmacol Toxicol Methods; 2017; 84():111-127. PubMed ID: 27956204
[TBL] [Abstract][Full Text] [Related]
16. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L
Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191
[TBL] [Abstract][Full Text] [Related]
17. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
[TBL] [Abstract][Full Text] [Related]
19. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
